

Title	Transforming Pathways Around Lipid Management in Primary Care in Buckinghamshire
Organisations Involved	Buckinghamshire Clinical Commissioning Group (CCG) and Amgen Limited
Joint Working Project Description	<p>This Project was agreed as part of the Accelerated Access Collaborative (AAC), which was formed to bring industry, government and the NHS together to remove barriers to uptake of innovation products from 7 high-potential technology areas, so that NHS patients could have faster access to certain products that can transform care.</p> <p>PCSK9 inhibitors for the management of hypercholesterolemia were selected as one of the seven NICE recommended rapid uptake products to increase patient access and remove barriers across the health innovation landscape.</p> <p>Funding was made available through the Accelerated Access Collaborative Pathway Transformation Fund (PTF) to help NHS organisations integrate the rapid uptake products into everyday practice. and to improve equality of access to these products.</p> <p>The PTF, in relation to PCSK9 inhibitors, combined funding from NHS England, Amgen and Sanofi for selected projects to meet the AAC objectives and increase PCSK9i uptake by addressing barriers.</p> <p>19 applications relating to PCSK9 inhibitors from 12 AHSNs were submitted to the AAC for PTF funding and 6 were selected.</p> <p>Buckinghamshire CCG and Amgen were working in partnership under a joint working agreement to transform lipid management pathways in primary care by</p> <ul style="list-style-type: none"> • The creation of a Pharmacist-Led Lipid Management Service • Development of a clear lipid management pathway for primary care • Establishing a “Virtual” Consultant-Led Lipid Clinic • Improved coding <p>After baselining the current quality of data and coding, a strategy to enhance the frequency and accuracy of coding was to be put in place. Outcomes data was to be captured and used to refine and optimise the service. This will be critical to support the case for sustainability beyond the pilot.</p>
Expected Outcomes	Predicted benefit to patients <ul style="list-style-type: none"> • Patients might expect more equitable and consistent care as well as improved and quicker access to care, better education around FH, better access to treatment options, improvement in clinical markers such as lipid levels, a clearer pathway of care with care being delivered closer to home and a better experience of the system.

	<p>Predicted benefit to NHS:</p> <ul style="list-style-type: none">• Decrease in numbers of patients reviewed with suboptimal lipid control in Bucks• Increases in numbers of patients with changes to statin therapy, prescribed adjunctive ezetimibe• Increased Patients referred, assessed and potentially initiated on PCSK9i• Reduce numbers of patients at risk of secondary CVD <p>Predicted benefit to Amgen:</p> <ul style="list-style-type: none">• The project aims to increase the hypercholesterolaemia and mixed dyslipidaemia diagnosis rates. Patients diagnosed with these conditions will be treated with cholesterol lowering medicines which may include an Amgen medicine for suitable patients in line with NICE TA394 and or local / national guidelines.• Greater customer understanding• Improved reputation through partnering with the AAC initiative <p>The results of the project were to be written up to enable the learnings from the project to be shared.</p>
--	--

GBR-NP-0225-80024 February 2025